MUMBAI, India, Sept. 7 -- Intellectual Property India has published a patent application (202617085183 A) filed by Shijiazhuang Yiling Pharmaceutical Co. , Ltd. on July 11, 2026, for Tricyclic Fused Heterocyclic Pde3/4 Dual Inhibitor, And Preparation And Use Therefor.
Inventors include Jia, Zhenhua; Wang, Hongtao; Hou, Yunlong; Qi, Hui; Mi, Yao; Hao, Yuanyuan; Tong, Yanan; Li, Faguang; Zhang, Pengfei; Hao, Mengan; Wang, Xiaohang; and Xu, Duo.
The application for the patent was published on September 04, 2026, under issue no. 36/2026.
Abstract: The invention discloses a tricyclic fused heterocyclic PDE3/4 dual inhibitor, and a preparation and use therefor. Specifically provided is a compound having structural formula (I) or a pharmaceutically acceptable form thereof, wherein each substituent is as defined in the description, respectively. The compound or the pharmaceutically acceptable form thereof can be used as a phosphodiesterase inhibitor and has high activity.
Disclaimer: Curated by HT Syndication.
